硫唑嘌呤治疗克罗恩病的长期疗效与安全性分析

Study on long - term efficacy and safety of azathioprine in treatment of patients with Crohn's disease

目的探讨硫唑嘌呤(AZA)治疗克罗恩病(CD)患者的长期疗效并分析其安全性。方法回顾分析收治于的CD患者42例,随访并监测AZA治疗第12、24、48、72、96周的临床疗效,分析经AZA治疗前与治疗后的CD的临床缓解程度及生物学评估,同时监测其不良反应。结果在应用AZA前CD活动指数(CDAI)评分160～470分,平均(289.12±102.57)分,在应用AZA后CDAI平均为(143.29±38.26)分,平均下降(145.83±64.31)分,差异有显著性(P<0.05);AZA治疗12、24、48、72、96周完全缓解率分别为52.4%、54.8%、61.9%、59.5%、57.1%;血红蛋白、基础状态血清蛋白、红细胞沉降率、C-反应蛋白治疗前与治疗后比较,差异具有显著性(P<0.05)。结论除少数患者发生不良反应外,AZA治疗CD具有长期疗效,可维持较长时间的临床缓解。

Objective To explore the efficacy and safety of azathioprine（AZA） in treatment of patients with Crohn＇s disease（CD） and to analyze its long-term efficacy and safety.Methods The clinical data of 42 patients with CD admitted to this hospital followed-up and monitored for 12,24,48,72 and 96 weeks were retrospectively analyzed.The condition of patients with Crohn＇s disease before AZA treatment and clinical condition and extent of mitigation after treatment and biological assessment and adverse reactions were monitored.Results Before application of AZA,CDAI scores were 160 to 470（with an average of 289.12） points,and the average of CDAI scores after application of AZA were 143.29 points,the average scores had been decreased for 145.83 points,and their difference was statistically significant（P 0.05）.After AZA treatment for12,24,48,72 and 96 weeks,the complete remission rate reached 40.7%,54.8%,61.9%,59.5% and 57.1% respectively.The difference in blood level of hemoglobin,basic state of serum protein,erythrocyte sedimentation rate and C-reactive protein before treatment and after treatment was significant（P 0.05）.Conclusion Apart from a small number of patients with adverse reactions,AZA treatment in patients with Crohn＇s disease has long-term efficacy,clinical remission can be maintained for a long time.